SCHEMBL1758083

SCHEMBL1758083

O=Cc1cncn1Cc1ccc(Cl)cc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 11/20 0.68
CYP11B2 P19099 11/20 0.68
CYP19A1 P11511 2/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2B6 P20813 1/20 0.41
MAPK1 P28482 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
VEGFA P15692 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
HSD17B10 Q99714 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
IDO1 P14902 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PKM P14618 1/20 0.39
KCNH2 Q12809 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8133106 0.95 CYP11B1 (0.63) CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6
SCHEMBL7986619 0.85 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1IDO1
SCHEMBL7700254 0.85 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1IDO1ALDH1A1
SCHEMBL7696780 0.85 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1CYP2A6HTT
SCHEMBL8140959 0.85 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1IDO1ALDH1A1
SCHEMBL765399 0.85 CYP11B1 (0.67) CYP11B1CYP11B2CYP19A1HTTSMN1; SMN2
SCHEMBL1757759 0.85 CYP11B1 (0.66) CYP11B1CYP11B2CYP19A1IDO1ALDH1A1
SCHEMBL7696643 0.85 CYP11B1 (0.66) CYP11B1CYP11B2CYP19A1HSD17B10IDO1
SCHEMBL8143815 0.84 CYP11B1 (0.62) CYP11B1CYP11B2MAPK1HTTSMN1; SMN2
SCHEMBL8135755 0.84 CYP11B1 (0.65) CYP11B1CYP11B2IDO1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114350-A1 INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2025-04-10 US disclosed
US-7943635-B2 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2011-05-17 US disclosed
US-20080255191-A1 BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINE AND QUINAZOLINE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS ANGIBAUD PATRICK RENE 2008-10-16 US disclosed
US-7241777-B2 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US disclosed
EP-1490065-B1 BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINONE AND QUINAZOLINONE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2007-06-13 EP disclosed
US-20050171111-A1 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2005-08-04 US disclosed
EP-1490065-A1 BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINONE AND QUINAZOLINONE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-29 EP disclosed
WO-2003080058-A1 BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINE AND QUINAZOLINE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS JANSSEN PHARMACEUTICA. N.V. (BE) 2003-10-02 WO disclosed
US-20020156113-A1 Farnesyl transferase inhibitors; anticancer agents LES LABORATOIRES SERVIER (FR) 2002-10-24 US disclosed
WO-2002057257-A1 CYCLO`C!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREFOR LES LABORATOIRES SERVIER (FR) 2002-07-25 WO disclosed
WO-2002057258-A1 CYCLO`D!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREOF LES LABORATOIRES SERVIER (FR) 2002-07-25 WO disclosed
EP-1225170-A2 Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier S.A. (FR) 2002-07-24 EP disclosed
WO-2001009124-A1 8-CARBONYL CHROMAN DERIVATIVES, PREPARATION AND THERAPIC USE THEREOF AVENTIS PHARMA S.A. (FR) 2001-02-08 WO disclosed
WO-2001009127-A1 BENZOXAZINE DERIVATIVES AND THEIR THERAPEUTIC USE AVENTIS PHARMA S.A. (FR) 2001-02-08 WO disclosed
EP-1054882-A1 CONDENSED HETEROCYCLIC SYSTEM DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Aventis Pharma S.A. (FR) 2000-11-29 EP disclosed
WO-1999041248-A1 CONDENSED HETEROCYCLIC SYSTEM DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA S.A. (FR) 1999-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114350-A1 INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS FNTA, FNTB, FDPS CYP11B1 3101/4885CYP11B2 3669/4885CYP19A1 3254/4885
US-20020156113-A1 Farnesyl transferase inhibitors; anticancer agents COASY, FNTA, FNTB CYP11B1 147/4885CYP11B2 399/4885CYP19A1 537/4885
US-20050171111-A1 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors FNTA, FNTB, RCE1 CYP11B1 300/4885CYP11B2 290/4885CYP19A1 317/4885
US-20080255191-A1 BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINE AND QUINAZOLINE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS FNTA, FNTB, RCE1 CYP11B1 266/4885CYP11B2 267/4885CYP19A1 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.